Semaphorin 3A (SEMA3A) represents a compelling biological target implicated in axonal guidance, tumor angiogenesis, immune regulation, and tissue fibrogenesis. However, targeting secreted semaphorins presents distinct off-target toxicity, mechanism redundancy, and translational clinical trial risks. This case study details how an R&D strategy team executed an evidence-based risk profiling assessment to evaluate SEMA3A pharmacological inhibition prior to committing Phase I clinical...